Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Primary Hypercholesterolemia or Mixed Hyperlipidemia

Interventions

DRUG

QLC7401

QLC7401 combined with lipid-lowering agents

DRUG

Placebo

Placebo combined with lipid-lowering agents

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY